NaturalPedia > Bristol-myers

Quotes about Bristol-myers from the world's top natural health / natural living authors

Share

Tweet

Email to a friend   |  Click here for FREE email alerts

page 1 of 3 | Next ->

"Which was nothing compared to the stock options held by the CEO of bristol-myers Squibb, which amounted to $227 million. And it's not just the CEOs: in 2000, the average unexercised stock options of the top executives at Merck were $73 million; at bristol-myers Squibb, $65 million; at Pfizer, $54 million; at Eli Lilly, $33 million." - Charles Barber, Comfortably Numb: How Psychiatry Is Medicating a Nation (Get the book.)

"Kathleen Slattery-Moschkau is a former rep who carried the bag for nine years for bristol-myers Squibb and Johnson & Johnson before quitting to write and direct Side Effects, an independent film about a fictional drug rep. She recalls that the pressure on reps to hit their quotas was intense. "If Pfizer was having a dinner at a really nice restaurant, you had to come up with [Green Bay] Packers tickets—and a bus to the game," she says. As reps upped the gift-giving ante, doctors began feeling entitled to increasingly luxurious favors." - Shannon Brownlee, Overtreated: Why Too Much Medicine Is Making Us Sicker and Poorer (Get the book.)

"The one thing we can know is that the denials of the evidence of such a relationship in the 2001 cholesterol guidelines and by the authors of the PROSPER article (sponsored by bristol-myers Squibb) suggest that the principle "First do no harm," which should be fresh in our minds from the increased rate of breast cancer caused by HRT, seems, once again, to have been forgotten." - John Abramson, Overdosed America: The Broken Promise of American Medicine (P.S.) (Get the book.) "The FDA seemed particularly irked because, the letter said, it had sent two less severe letters to bristol-myers Squibb for similar "overstated" and "unsubstantiated" claims in 2001. If stroke prevention is the goal, lowering cholesterol with a statin drug is hardly the first strategy we should turn to. According to the data presented by Giles at the CDC conference, an elevated cholesterol level increases the risk of stroke one-eighth as much as diabetes, one-eighth to one-sixteenth as much as elevated blood pressure, and less than a thirtieth as much as a sedentary lifestyle." - John Abramson, Overdosed America: The Broken Promise of American Medicine (P.S.) (Get the book.) "However, the site does mention that the two nonprofit organizations participating in this educational initiative have a number of "corporate partners," namely AstraZeneca, Aventis, bristol-myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Merck/Schering-Plough, Monarch, Novartis, Pfizer, and Wyeth. When corporate partners fund the flow of information, the message is likely to accentuate treatment strategies that are in their interest and downplay those that are not. For example, fewer than one-third of the diabetics in the United States get adequate exercise." - John Abramson, Overdosed America: The Broken Promise of American Medicine (P.S.) (Get the book.)

"There is a new magazine, bp (underwritten by Pfizer and bristol-myers Squibb), offering hope for people suffering from bipolar disorder. Monk, a show about a detective with obsessive-compulsive disorder who uses his illness adaptively to perceive things that normal people can't, is one of the most popular programs on cable television and has received a gaggle of Screen Actors Guild, Emmy, and Edgar awards." - Charles Barber, Comfortably Numb: How Psychiatry Is Medicating a Nation (Get the book.)

"In one recent case, a Louisiana judge ordered bristol-myers Squibb, the company that manufactures and distributes Prolixin, to pay $2 million to a fifty-two-year-old woman who developed severe and disabling tardive dyskinesia after taking the drug for five years. Among her symptoms were muscle spasms and abnormal movements of the face, neck, shoulders, and extremities, as well as impaired speech and breathing. More than thirty years ago, according to Dr." - Gary Null and Amy McDonald, The Food-Mood Connection: Nutrition-based and Environmental Approaches to Mental Health and Physical Wellbeing (Get the book.)

"In 2004 the Securities and Exchange Commission (SEC) ordered bristol-myers Squibb to pay $ 150 million to settle charges that it inflated its revenue by $1.5 billion in 2000 and 2001. The penalty was one of the largest levied against a company accused of accounting fraud.26 The settlement concluded a two-year SEC investigation of the company, but the bad news for bristol-myers Squibb didn't stop there. A separate criminal investigation by the U.S." - Peter Rost, The Whistleblower: Confessions of a Healthcare Hitman (Get the book.)

"And it's not just the CEOs: in 2000, the average unexercised stock options of the top executives at Merck were $73 million; at bristol-myers Squibb, $65 million; at Pfizer, $54 million; at Eli Lilly, $33 million.5 Even after the woes that Big Pharma experienced between 2004 and 2007—the withdrawal of Vioxx from the market, the loss of half of the injectable flu vaccines because of quality control problems, and a growing public awareness of profiteering and an all-too-cozy relationship with the Bush administration—no one should worry unduly about the industry's fortunes." - Charles Barber, Comfortably Numb: How Psychiatry Is Medicating a Nation (Get the book.)

"The penultimate paragraph describes just how to keep those lines open, including a request for a $250,000 donation from bristol-myers Squibb to the Republican National Committee. With tens of billions of dollars a year on the line for the drug industry, what was a mere $250,000? Perhaps the storm clouds were being actively seeded. Drug COfTlparties, government, doctors, patients, insurers. Health care costs keep rising, with no end in sight, and despite the myths about the excellence of our medical care, we are not realizing commensurate improvements in our health." - John Abramson, Overdosed America: The Broken Promise of American Medicine (P.S.) (Get the book.)

"But aspirin found an unprecedented market around the world, including the developing world. bristol-myers, American Home, and Miles Laboratories (Alka-Seltzer) joined Sterling in evolving from patent-medicine firms into lucrative industrial powerhouses competing among themselves and with I. G. Farben for the sale of aspirin and aspirin-containing preparations. Aspirin sales grew unchallenged until the 1960s. Tons were consumed each day in the United States. For most of the twentieth century, aspirin overdose was a leading cause of emergency-room visits and drug-induced fatality." - Nortin M. Hadler MD, Worried Sick: A Prescription for Health in an Overtreated America (Get the book.)

"Another industry big-wig, retired bristol-myers Sguibb Vice-Chairman, Bruce Gelb, was a Bush Pioneer who also had longstanding ties to the Bush family. Gelb was appointed chief of the US Information Agency, and ambassador to Belgium, by the first President Bush. Before the 2000 election, bristol-myers executives reportedly were pressured to make maximum donations to the Bush campaign and reluctant donors were warned that CEO, Charles Heimbold Jr, whom Bush later named ambassador to Sweden, would be informed if they failed to give, according a September 5, 2003 New York Times article." - Dr David W Tanton, Ph.D., Antidepressants, Antipsychotics, And Stimulants - Dangerous Drugs on Trial (Get the book.)

"In 1992, the NIH licensed Taxol to bristol-myers Squibb, which then generated $2 billion of revenue per year on the sale of the product. So again, quite a few blockbuster medications are clearly developed by public funding, academic medical centers, and foreign academic centers, whilst the pharmaceutical industry gets additional tax-advantages. So, in what are the pharmaceutical companies investing? Yes, in advertising, advertising, advertising. And in sales, sales, sales. The physicians are swamped with pharmaceutical sales representatives." - Kenneth W Thomas, Ron Gilbert, Gerd Schaller, Side Effects: The Hidden Agenda of the Pharmaceutical Drug Cartel (Get the book.)

"Wagner has received research support from Abbott, bristol-myers Squibb, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Organon, Pfizer, and Wyeth-Ayerst; has served as a National Institute of Mental Health consultant to Abbott, bristol-myers Squibb, Cyberonics, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Novartis, Otsuka, Janssen, Pfizer, and UCB Pharma; and has participated in speaker's bureaus for Abbott, Eli Lilly, GlaxoSmithKline, Forest Laboratories, Pfizer, and Novartis.2 The study's principal statistician was Dr. Ruoyong Yang. Both he and another of the study's authors, Dr." - Dr. Timothy Scott, America Fooled: The Truth About Antidepressants, Antipsychotics and How We've Been Deceived (Get the book.)

"And it was not just bristol-myers that had devised such a strategy. Its executives were only following in the footsteps of their competitors, the other masters of the medicine trade. Third World countries, where most real disease exists, had long suffered because the industry's business plans did not include them. Of the 1,223 new drugs that reached the market between 1975 and 1997, only thirteen of them, or just 1 percent, treated the deadly or debilitating diseases found in the tropics, where most people are poor." - Melody Petersen, Our Daily Meds: How the Pharmaceutical Companies Transformed Themselves into Slick Marketing Machines and Hooked the Nation on Prescription Drugs (Get the book.) "Instead, bristol-myers was their licensed seller and marketer. The most troublesome problem with the Tufts estimate of the cost of discovering a drug, however, is that there is no way to verify it. The pharmaceutical companies' actual research costs are one of the world's most closely guarded industrial secrets. In the 1970s and 1980s the companies waged a decade-long legal battle to keep even government auditors from reviewing the costs of their research laboratories." - Melody Petersen, Our Daily Meds: How the Pharmaceutical Companies Transformed Themselves into Slick Marketing Machines and Hooked the Nation on Prescription Drugs (Get the book.) "The federal government then paid to manufacture the drug and to test it in patients, before granting a license to bristol-myers to sell it. In fact, of the nation's twenty-one most important drugs introduced between 1965 and 1992, fifteen were developed using knowledge from federal-funded research, according to a report in 2000 by the Joint Economic Committee of Congress, then headed by Republican senator Connie Mack. Among the drugs mentioned by that report was the cancer drug cisplatin." - Melody Petersen, Our Daily Meds: How the Pharmaceutical Companies Transformed Themselves into Slick Marketing Machines and Hooked the Nation on Prescription Drugs (Get the book.)

"Joining forces to provide the Nutrition in Medicine program and the Medical Nutrition Curriculum Initiative are no less than the Dannon Institute, the Egg Nutrition Board, the National Cattlemen's Beef Association, the National Dairy Council, Nestle Clinical Nutrition, Wyeth-Ayerst Laboratories, bristol-myers Squibb Company and others. The reason that medical schools fail to teach medical students the truth about health is that drug companies fund their scholarships and want to create doctors who function as professional and legal drug pushers." - Susan E. Schenck, The Live Food Factor: The Comprehensive Guide to the Ultimate Diet for Body, Mind, Spirit & Planet (Get the book.)

"On a stage with a multicolored backdrop, the company's top two executives, Charles Heimbold and Peter Dolan, stepped up to announce that bristol-myers was embarking on what they called the MegaDouble plan. The company would now focus its efforts, the executives said, on marketing only those drugs with the potential to bring in several billion dollars a year. They called these products megablockbusters. Dolan, the company's president, laid out more details of the Mega-Double plan in an article in a magazine published internally for employees. " - Melody Petersen, Our Daily Meds: How the Pharmaceutical Companies Transformed Themselves into Slick Marketing Machines and Hooked the Nation on Prescription Drugs (Get the book.)

"Tylenol would soon do battle with Datril, Bristol-Myers's version. Both made important inroads into the aspirin market as an analgesic (painkiller) and antipyretic (lowers fever). Acetaminophen has little of aspirin's effect on the swelling, redness, and warmth that characterizes inflammatory lesions, just the tenderness and painfulness. Acetaminophen does not cause gastropathy, or shallow erosions of the lining of the stomach. Nonetheless, this was the start of the erosion of aspirin's dominance. The Boots Company is a venerable British retail drug chain." - Nortin M. Hadler MD, Worried Sick: A Prescription for Health in an Overtreated America (Get the book.) "Of those with high cholesterol, 6,595 agreed to participate in a five-year, randomized placebo-controlled trial of pravastatin, the "statin" marketed under the brand name Pra-vachol by the bristol-myers Squibb Pharmaceutical Company, which funded the trial. That means that every morning for the five years, these men took a pill. For 3,302 men, that pill contained 40 mg of pravastatin, and for the remainder the morning pill contained a pharmacologically inert substance, a placebo. The main results are presented in Table 1." - Nortin M. Hadler MD, Worried Sick: A Prescription for Health in an Overtreated America (Get the book.)

"Illustratively, using taxpayers' money, NCI paid for the research and development of Taxol, an anticancer drug now manufactured by bristol-myers Squibb. Following completion of clinical trials — an extremely expensive process in itself — the public paid further for developing the drug's manufacturing process. Once completed, NCI officials gave bristol-myers Squibb the exclusive right to sell Taxol at an inflationary price. As investigative journalist, Joel Bleifuss, wrote in a 1995 In These Times article, "Bristol-Myers Squibb sells Taxol to the public for $4." - Samuel S. Epstein, M.D., The Politics of Cancer Revisited (Get the book.)

"Many executives involved in the $2 billion purchase of marketing rights for Erbitux by bristol-myers have resigned. [New York Times, Feb. 11, 2004] What, no treatment for metastasis? Again, Clifton Leaf of Fortune Magazine speaks out about the failings of cancer treatment. In the end, it is not localized tumors that kill people with cancer; it is the process of metastasis—an incredible 90% of the time. That's because when most malignant solid tumors are diagnosed, they are typically quite large already—the size of a grape, perhaps, with more than a billion cells in the tumor mass." - Bill Sardi, You Don't Have to be Afraid of Cancer Anymore (Get the book.)

"This recall follows the removal of Serzone by bristol-myers from the Canadian and European markets on January 8, 2003, because it had been linked to 26 deaths. The drug was yanked off the Canadian and European market in January 2003, but it continued to sell here in the U.S. for another 14 months. The FDA issued a "black box warning" label regarding Serzone in 2001, because of a suspected side effect that could cause life-threatening damage to the liver. How about Redux or Fen-Phen?" - Craig Pepin-Donat, The Big Fat Health and Fitness Lie (Get the book.)

"The Dannon Institute, Egg Nutrition Board, National Cattlemen's Beef Association, National Dairy Council, Nestle Clinical Nutrition, Wyeth-Ayerst Laboratories, bristol-myers Squibb Company, Baxter Healthcare Corporation and others have all joined forces to produce a Nutrition in Medicine program and the Medical Nutrition Curriculum Initiative.9'10 Do you think that this all-star team of animal foods and drug industries representatives is going to objectively judge and promote optimal nutrition, which science has shown to be a whole foods, plant-based diet that minimizes the need for drugs?" - T. Colin Campbell, Ph.D. and Thomas M. Campbell II, The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Health (Get the book.)

"This pitted an 80mg daily dose of Pfizer's Lipitor against a 40mg daily dose of bristol-myers Squibb's Pravachol in 4,000 patients who had been hospitalized for either acute heart attacks or unstable angina. This was funded by BMS in an attempt to show that lower was not necessarily better. The BMS drug was designed to reduce LDL cholesterol to 100, which according to US guidelines, is the target level for such patients. In contrast, the high-dose Lipitor was designed to reduce levels to 70, substantially lower than the guidelines." - Jacky Law, Big Pharma: Exposing the Global Healthcare Agenda (Get the book.) "Lipitor. bristol-myers Squibb was naturally quick to point out that the images didn't actually prove anything; but to most people, Lipitor won convincingly. According to the Wall Street Journal, Pfizer said it intended to talk to the regulators about whether the findings are sufficient to change its product label so it can add the effect to its marketing programme.12 If validated in further studies, they could lead experts to lower national LDL for high-risk patients to below the current recommended level of 100. Then came the PROVE-IT study, the results of which were announced in March 2004." - Jacky Law, Big Pharma: Exposing the Global Healthcare Agenda (Get the book.) "But others, such as bristol-myers Squibb, which markets one of the least potent statins, Pravachol, insist patients glean little incremental benefit by reducing their LDL levels too much. Doctors, and their patients, are naturally interested if lower really is better. But pharma companies are usually reluctant to pit their drugs against competitors in head-to-head studies, unless they have reason to believe the results would favour their product." - Jacky Law, Big Pharma: Exposing the Global Healthcare Agenda (Get the book.)

"You may recognize some of the following names: Aventis, King Pharmaceuticals, bristol-myers Squibb, Bayer, GlaxoSmithKline, Novartis, Pfizer, Roche, Abbott Laboratories, Genentech, Pharmacia, Astrazeneca, Natural-Source Vitamin E Association, and several others. These are the same companies that produce drugs that kill hundreds of thousands of people each year. Only these companies have the type of money that could fund such a study, representing their own interests, and not the public's. The next question is for what purpose was this study funded?" - Kevin Trudeau, More Natural Cures Revealed: Previously Censored Brand Name Products That Cure Disease (Get the book.)

"Even its manufacturer, bristol-myers Squibb, claimed that Serzone was mainly for people for whom all of the other antidepressants did not work. Yet its hepatotoxicity was clear, and reports during the years immediately after its release, both at the FDA and at Squibb, indicated that people were suffering from it. Worse, Serzone was a potent liver enzyme inhibitor, which meant that it prevented the liver from processing other drugs properly, leading to further injury from everything from statins to other central nervous system drugs." - Greg Critser, Generation Rx: How Prescription Drugs are Altering American Lives, Minds, and Bodies (Get the book.)

page 1 of 3 | Next ->

FAIR USE NOTICE: The research quoted here is provided under the protection of Fair Use provisions and published by the 501(c)3 non-profit Consumer Wellness Center for the purposes of public comment and education. Authors / publishers may submit books for consideration of inclusion here.

TERMS OF USE: Read full terms of use. Citations of text from NaturalPedia must include: 1) Full credit to the original author and book title. 2) Secondary credit to the Natural News Naturalpedia as a research resource and a link to www.NaturalPedia.com

This unique compilation of research is copyright (c) 2008, 2009 by the non-profit Consumer Wellness Center.

ABOUT THE CREATOR OF NATURALPEDIA: Mike Adams, the creator of NaturalPedia, is the editor of NaturalNews.com, the internet's top natural health news site, creator of the Honest Food Guide (www.HonestFoodGuide.org), a free downloadable consumer food guide based on natural health principles, author of Grocery Warning, The 7 Laws of Nutrition, Natural Health Solutions, and many other books available at www.TruthPublishing.com, creator of the earth-friendly EcoLEDs company (www.EcoLEDs.com) that manufactures energy-efficient LED lighting products, founder of Arial Software (www.ArialSoftware.com), a permission e-mail technology company, creator of the CounterThink Cartoon series (www.NaturalNews.com/index-cartoons.html) and author of over 1,500 articles, interviews, special reports and reference guides available at www.NaturalNews.com. Adams' personal philosophy and health statistics are available at www.HealthRanger.org.